tbuckley/cabot-search huggingface dataset:
Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During Direct‐Acting Antiviral Therapy
Authors: Hawwa Alao, Maggie Cam, Chithra Keembiyehetty, Fang Zhang, Elisavet Serti, Daniel Suarez, Heiyoung Park, Nicolaas H. Fourie, Elizabeth C. Wright, Wendy A. Henderson, Qisheng Li, T. Jake Liang, Barbara Rehermann, Marc G. Ghany
Journal: Hepatology (2018)

Hepatitis C virus (HCV) infection induces interferon (IFN)-stimulated genes (ISGs) and downstream innate immune responses. This study investigated whether baseline and on-treatment differences in these responses predict response versus virological breakthrough during therapy with direct-acting antivirals (DAAs). Thirteen HCV genotype 1b-infected patients who had previously failed a course of pegylated IFN/ribavirin were retreated with asunaprevir/daclatasvir for 24 weeks. After pretreatment biopsy, patients were randomized to undergo a second biopsy at week 2 or 4 on therapy. Microarray and NanoString analyses were performed on paired liver biopsies and analyzed using linear mixed models. As biomarkers for peripheral IFN responses, peripheral blood natural killer cells were assessed for phosphorylated signal transducer and activator of transcription 1 (pSTAT1) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and degranulation. Nine of 13 (69%) patients achieved sustained virological response at 12 weeks off therapy (SVR12), and 4 experienced virological breakthroughs between weeks 4 and 12. Patients who achieved SVR12 displayed higher ISG expression levels in baseline liver biopsies and a higher frequency of pSTAT1 and TRAIL-expressing, degranulating natural killer cells in baseline blood samples than those who experienced virological breakthrough. Comparing gene expression levels from baseline and on-therapy biopsies, 408 genes (±1.2-fold, P < 0.01) were differentially expressed. Genes down-regulated on treatment were predominantly ISGs. Down-regulation of ISGs was rapid and correlated with HCV RNA suppression. Conclusion: An enhanced IFN signature is observed at baseline in liver and blood of patients who achieve SVR12 compared to those who experience a virological breakthrough; the findings suggest that innate immunity may contribute to clearance of HCV during DAA therapy by preventing the emergence of resistance-associated substitutions that lead to viral breakthrough during DAA therapy.
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial
Authors: Vanesa Gregorc, Rabab M Gaafar, Adolfo Favaretto, Francesco Grossi, Jacek Jassem, Andreas Polychronis, Paolo Bidoli, Marcello Tiseo, Riyaz Shah, Paul Taylor, Silvia Novello, Alberto Muzio, Alessandra Bearz, Laurent Greillier, Floriana Fontana, Giulia Salini, Antonio Lambiase, Mary O'Brien
Journal: The Lancet Oncology (2018)
Neoatherosclerosis 5 Years After Bioresorbable Vascular Scaffold Implantation
Authors: Noriaki Moriyama, Koki Shishido, Yutaka Tanaka, Shohei Yokota, Takahiro Hayashi, Hirokazu Miyashita, Tatsuya Koike, Hiroaki Yokoyama, Takuma Takada, Takashi Nishimoto, Tomoki Ochiai, Kazuki Tobita, Futoshi Yamanaka, Shingo Mizuno, Masato Murakami, Saeko Takahashi, Shigeru Saito
Journal: Journal of the American College of Cardiology (2018)
Analysis of the Draft Genome of the Red Seaweed Gracilariopsis chorda Provides Insights into Genome Size Evolution in Rhodophyta
Authors: JunMo Lee, Eun Chan Yang, Louis Graf, Ji Hyun Yang, Huan Qiu, Udi Zelzion, Cheong Xin Chan, Timothy G Stephens, Andreas P M Weber, Ga Hun Boo, Sung Min Boo, Kyeong Mi Kim, Younhee Shin, Myunghee Jung, Seung Jae Lee, Hyung-Soon Yim, Jung-Hyun Lee, Debashish Bhattacharya, Hwan Su Yoon
Journal: Molecular Biology and Evolution (2018)

Red algae (Rhodophyta) underwent two phases of large-scale genome reduction during their early evolution. The red seaweeds did not attain genome sizes or gene inventories typical of other multicellular eukaryotes. We generated a high-quality 92.1 Mb draft genome assembly from the red seaweed Gracilariopsis chorda, including methylation and small (s)RNA data. We analyzed these and other Archaeplastida genomes to address three questions: 1) What is the role of repeats and transposable elements (TEs) in explaining Rhodophyta genome size variation, 2) what is the history of genome duplication and gene family expansion/reduction in these taxa, and 3) is there evidence for TE suppression in red algae? We find that the number of predicted genes in red algae is relatively small (4,803–13,125 genes), particularly when compared with land plants, with no evidence of polyploidization. Genome size variation is primarily explained by TE expansion with the red seaweeds having the largest genomes. Long terminal repeat elements and DNA repeats are the major contributors to genome size growth. About 8.3% of the G. chorda genome undergoes cytosine methylation among gene bodies, promoters, and TEs, and 71.5% of TEs contain methylated-DNA with 57% of these regions associated with sRNAs. These latter results suggest a role for TE-associated sRNAs in RNA-dependent DNA methylation to facilitate silencing. We postulate that the evolution of genome size in red algae is the result of the combined action of TE spread and the concomitant emergence of its epigenetic suppression, together with other important factors such as changes in population size.
In perfusion imaging–selected acute ischemic stroke, thrombectomy at 6 to 16 hours improved functional outcomes
Authors: Omar Damji, Eddy Lang
Journal: Annals of Internal Medicine (2018)

ACP Journal Club17 April 2018In perfusion imaging–selected acute ischemic stroke, thrombectomy at 6 to 16 hours improved functional outcomesOmar Damji, MSc, MD, Eddy Lang, MDOmar Damji, MSc, MDCumming School of Medicine, University of Calgary, Calgary, Alberta, Canada (O.D., E.L.)Search for more papers by this author, Eddy Lang, MDCumming School of Medicine, University of Calgary, Calgary, Alberta, Canada (O.D., E.L.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2018-168-8-042 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationAlbers GW, Marks MP, Kemp S, et al; DEFUSE 3 Investigators. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018;378:708-18. https://pubmed.ncbi.nlm.nih.gov/29364767Clinical Impact RatingsEmergency Med: Hospitalists: Neurology: References1 Powers WJ, Derdeyn CP, Biller J, et al; American Heart Association Stroke Council. 2015 American Heart Association/American Stroke Association focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46:3020-35. [PMID: 26123479] Google Scholar2 Phan K, Dmytriw AA, Maingard J, et al. Endovascular thrombectomy alone versus combined with intravenous thrombolysis. World Neurosurg. 2017;108:850-8.e2. [PMID: 28823660] Google Scholar3 Nogueira RG, Jadhav AP, Haussen DC, et al; DAWN Trial Investigators. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378:11-21. [PMID: 29129157] Google Scholar4 Sevick LK, Ghali S, Hill MD, et al. Systematic review of the cost and cost-effectiveness of rapid endovascular therapy for acute ischemic stroke. Stroke. 2017;48:2519-26. [PMID: 28716983] Google Scholar Author, Article, and Disclosure InformationAffiliations: Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada (O.D., E.L.)This article was published at Annals.org on 3 April 2018. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 17 April 2018Volume 168, Issue 8Page: JC42KeywordsBrainHemorrhagic strokeInfarctionIschemic strokeMagnetic resonance imagingNeuroimagingNeurologyNumber needed to treatRisk ratioStroke ePublished: 17 April 2018 Issue Published: 17 April 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Circulating microparticles and thrombotic risk in patients with HCV-related cirrhosis who underwent DAA treatment
Authors: A. Zanetto, Elena Campello, E. Franceschet, S. Shalaby, A. Ferrarese, S. Sciarrone, C. Becchetti, M. Gambato, G. Germani, M. Senzolo, P. Simioni, P. Burra, F.P. Russo
Journal: Journal of Hepatology (2018)
Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer's disease
Authors: Pengzhen Wang, Xiaoyao Zheng, Qian Guo, Peng Yang, Xiaoying Pang, Kang Qian, Wei Lu, Qizhi Zhang, Xinguo Jiang
Journal: Journal of Controlled Release (2018)
Electronic clinical decision algorithms for the integrated primary care management of febrile children in low-resource settings: review of existing tools
Authors: Kristina Keitel, Valérie D'Acremont
Journal: Clinical Microbiology and Infection (2018)

The lack of effective, integrated diagnostic tools poses a major challenge to the primary care management of febrile childhood illnesses. These limitations are especially evident in low-resource settings and are often inappropriately compensated by antimicrobial overprescription. Electronic clinical decision algorithms (eCDAs) have the potential to close these gaps by guiding antibiotic use and better identifying serious disease.This narrative review summarizes existing eCDAs, to provide an overview of their degree of validation and to identify gaps in current knowledge and prospects for future innovation.Structured literature review in PubMed and Embase complemented by Google search and contact with developers.Six integrated eCDAs were identified: three (eIMCI, REC and Bangladesh digital IMCI) based on Integrated Management of Childhood Illnesses (IMCI); four (SL electronic iCCM, MEDSINC, electronic iCCM and D-Tree electronic iCCM) on Integrated Community Case Management (iCCM); two (ALMANACH, MSFeCARE) with a modified IMCI content; and one (ePOCT) that integrates novel content with biomarker testing. The types of publications and evaluation studies varied greatly: the content and evidence base were published for two (ALMANACH and ePOCT) and ALMANACH and ePOCT were validated in efficacy studies. Other types of evaluations, such as compliance and acceptability, were available for D-Tree electronic iCCM, eIMCI and ALMANACH. Several evaluations are still ongoing. Future prospects include conducting effectiveness and impact studies using data gathered through larger studies to adapt the medical content to local epidemiology, improving the software and sensors, and assessing factors that influence compliance and scale-up.eCDAs are valuable tools that have the potential to improve management of febrile children in primary care and increase the rational use of diagnostics and antimicrobials. Next steps in the evidence pathway should be larger effectiveness and impact studies (including cost analysis) and continuous integration of clinically useful diagnostic and treatment innovations.
Abstract 15926: Mechanics of Mitral Regurgitation in Peripartum Cardiomyopathy
Authors: Josef J Marek, Dennis McNamara, Mohamed Ahmed, Lori A Blauwet, Joan Briller, Richard J Sheppard, Rami Alharethi, John Gorcsan
Journal: Circulation (2013)

Background: Peripartum cardiomyopathy (PCM) is an important disease often associated with myocardial recovery. The mechanisms of mitral regurgitation (MR) in PCM related to recovery are unclear. Me...
Association of Repeated Measurements With Blood Pressure Control in Primary Care
Authors: Douglas Einstadter, Shari D. Bolen, James E. Misak, David S. Bar-Shain, Randall D. Cebul
Journal: JAMA Internal Medicine (2018)

This observational cohort study evaluated the effect of a second blood pressure (BP) measurement on the rate of BP control among more than 38 000 patients with diagnosed hypertension and who were followed in primary care.
Review of GP partnership model will be headed by LMC leader
Authors: Abi Rimmer
Journal: BMJ (2018)

The government has appointed a GP and local medical committee (LMC) chief executive to chair an independent review of how the GP partnership model needs to change.

Nigel Watson is chief executive of Wessex LMC and a member of the BMA’s General Practitioners Committee (GPC), and has been a GP in the New Forest for over 30 years.

The final terms of the review have yet to be finalised and will be decided by …
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)
Authors: Alessandra Larocca, Sandra Maria Dold, Sonja Zweegman, Evangelos Terpos, Ralph Wäsch, Mattia D’Agostino, Sophia Scheubeck, Hartmut Goldschmidt, Francesca Gay, Michele Cavo, Heinz Ludwig, Christian Straka, Sara Bringhen, Holger W. Auner, Jo Caers, Martin Gramatzki, Massimo Offidani, Meletios A. Dimopoulos, Hermann Einsele, Mario Boccadoro, Pieter Sonneveld, Monika Engelhardt
Journal: Leukemia (2018)
Redefining Informed Consent as Part of Consent Training in Pediatrics—Reply
Authors: Alan R. Tait, Raymond J. Hutchinson
Journal: JAMA Pediatrics (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
HCV modifies EGF signalling and upregulates production of CXCR2 ligands: Role in inflammation and antiviral immune response
Authors: Christina Groepper, Kerstin Rufinatscha, Nadja Schröder, Sabine Stindt, Christian Ehlting, Ute Albrecht, Hans H. Bock, Ralf Bartenschlager, Dieter Häussinger, Johannes G. Bode
Journal: Journal of Hepatology (2018)
What impact do the new direct acting antiviral drugs have on the patients’ quality of life?
Authors: M. Gentili, C.F. Magni, C. Carnovale, E. Cesari, D. Cattaneo, M. Schiavini, S. Landonio, F. Niero, V. Scalzi, S. Vimercati, S. Radice, E. Clementi, G. Rizzardini
Journal: Journal of Hepatology (2018)
HBV reactivation and changes in interferon-stimulated gene expression during treatment of direct-acting antivirals for HCV: Analyses in a novel in vitro model for HBV-HCV coinfection using human induced pluripotent stem cell-derived hepatic cells
Authors: Y. Asahina, S. Kaneko, S. Kakinuma, A. Kamiya, M. Miyoshi, T. Tsunoda, E. Inoue, S. Nitta, A. Sato, H. Nagata, F. Kawai-Kitahata, M. Murakawa, Y. Itsui, M. Nakagawa, S. Azuma, M. Watanabe
Journal: Journal of Hepatology (2018)
The Rapid-EC study – A feasibility study of point-of-care testing in community clinics targeted to people who inject drugs in Melbourne, Australia
Authors: B. Williams, A. Pedrana, J. Howell, J. Doyle, A. Thompson, F. Bramwel, D. Membrey, M. Mcpherson, C. Layton, B. Draper, J. Roney, N. Latham, M. Hellard
Journal: Journal of Hepatology (2018)
De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era
Authors: Allison J. Kwong, W. Ray Kim, Jennifer A. Flemming
Journal: Hepatology (2018)

The risk of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV) receiving direct acting antivirals (DAAs) has been debated. This study aims to describe the incidence of HCC among patients listed for liver transplantation (LT) in the DAA era. Individuals with cirrhosis listed for LT from January 2003 to December 2015 were identified using the Scientific Registry for Transplant Recipients database. Patients with HCC at listing or HCC exception within 180 days were excluded. Patients were divided into three eras based on listing date: eras 1 (2003‐2010), 2 (2011‐2013), and 3 (2014‐2015). Incidence rates of HCC were calculated by era and compared using incident rate ratios (IRRs). The association between HCC and listing era was evaluated using Cox regression and competing risk analyses, the latter considering death and LT as competing events. Of the 48,158 eligible wait‐list registrants, 3112 (6.5%) received HCC exceptions after a median of 493 days. In 20,039 individuals with HCV, the incidence of HCC was 49% higher in era 3 versus era 1 (IRR 1.49, 95% confidence interval [CI] 1.24‐1.79). In multivariate analysis, those in era 3 had a higher hazard of HCC compared with era 1 (hazard ratio 1.22, 95% CI 1.01‐1.48). However, in multivariable competing risks analysis, with death and LT considered as competing events for de novo HCC, era was no longer associated with HCC (subdistribution hazard ratio 0.83, 95% CI 0.69‐1.00). Conclusion: In this large population‐based cohort of LT registrants, the incidence of HCC among HCV patients has increased in the DAA era. Competing risks analysis suggests that this may be explained by changes in rates of LT and wait‐list mortality in the HCV population during this time. (H epatology 2018; 00:000‐000).
Updated follow-up analysis in the REP 401 protocol: Treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon alfa-2a
Authors: A. Vaillant, M. Bazinet, V. Pantea, G. Placinta, I. Moscalu, V. Cebotarescu, L. Cojuhari, P. Jimbei, L. Iarovoi, V. Smesnoi, T. Musteata, A. Jucov, A. Krawczyk
Journal: Journal of Hepatology (2018)
Non inferiority of combination of slow continuous albumin, furosemide with low dose Terlipressin with Noradrenaaline infusion in ACLF patients in comparison to slow continuous albumin, furosemide and Terlipressin
Authors: G. Pandey, A. Kumar, M. Durgappa, A. Singh, A. Nehra, K. Vp, P. Sharma, P. Mishra, S. Mohindra, V. Saraswat
Journal: Journal of Hepatology (2018)
Elderly patients with colorectal cancer: Treatment modalities and survival in France from the ThInDiT observational cohort study.
Authors: Solene Doat, Anne Thiébaut, Solene Samson, Philippe Ricordeau, Didier Guillemot, Emmanuel Mitry
Journal: Journal of Clinical Oncology (2012)

e14065 Background: More than 40% of the colorectal cancers (CRC) occur in elderly patients. Epidemiological data suggests that treatment modalities in this population differ from younger patients. We analysed the management of CRC patients in the real life in France using the French national health insurance system database. Methods: ThInDiT (Therapeutic Innovations in Digestive Tumors) is an observational cohort of 31 665 incident CRC diagnosed between April 1 st and December 31th 2009 and registered in the French national health insurance system database. Using this cohort, we compared disease characteristics and treatment modalities within the first year of diagnosis between elderly (age &gt;= 75) and younger patients (&lt;75 years). Results: Elderly patients (pts) represented 42% (13 255/31 665) of the cases. They had more frequently an advanced stage at diagnosis (synchronous metastases: 20.5% vs 19.5% p=0.02, occlusion: 17% vs 11% p&lt;0.0001). Pts with a localised disease (n=25 353): Surgery was performed in more than 80% of the cases in both age groups, delay between diagnosis and surgery was significantly shorter in elderly pts (8 vs 23 days p&lt;0.0001) suggesting that emergency surgery was more frequent in this age group. An adjuvant chemotherapy (CT) was less frequently prescribed among elderly pts (15% vs 29% p&lt;0.0001), 50% of the elderly received a 5FU alone whereas 79% of the younger pts had an oxaliplatin-based adjuvant CT. Pts with synchronous metastases (n= 6 312): Administration of palliative CT in elderly vs younger pts: 48% vs 85%, p&lt;0.0001. CT regimen: LV5FU2 or capecitabine (30% vs 10%), Oxaliplatin-5FU (30% vs 34%), CT + bevacizumab (20% vs 35%) respectively. Elderly pts received less frequently a second or third line of CT than younger pts. Median overall survival was 8.4 months in elderly and 22.1 months in younger pts. Conclusions: Elderly patients represent more than 40% of incident CRC in France, they have a more advanced disease at diagnosis than younger pts. Treatment modalities are different among elderly and younger pts. Elderly pts have a worse prognosis than younger pts.
Associations of incidence of common adverse events (AEs) and survival outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line chemotherapy: Findings from 9,812 pts in the ARCAD database.
Authors: Danielle Angela Ferraro, John Raymond Zalcberg, Qian Shi, Jeffrey P. Meyers, Matthew T. Seymour, Leonard Saltz, Tim Maughan, Richard M. Goldberg, Eric Van Cutsem, Volker Heinemann, Herbert Hurwitz, Alfredo Falcone, Eduardo Diaz-Rubio, Benoist Chibaudel, Charles S. Fuchs, Rainer Porschen, Carsten Bokemeyer, Aimery De Gramont, Tim Price, Richard Adams
Journal: Journal of Clinical Oncology (2018)

617 Background: There is limited, often conflicting evidence about AE timing, severity or associations with outcomes with the use of cytotoxic agents in cancer treatment. We investigated the impact on overall survival (OS) and progression-free survival (PFS) of selected common AEs (neutropenia, diarrhea, nausea, vomiting, neuropathy) occurring in patients receiving first line oxaliplatin (Oxa)- and/or irinotecan(Iri)-based regimens for mCRC. Methods: The CTCAE grading scores of at least one AE of interest were available on 9812 pts treated with chemotherapy alone (median age 63; 62.4% male, 50.1% ECOG PS 0) from 17 1 st -line randomized trials. Patients who also received biologics were excluded in the primary analyses. AEs occurring during the first 6 weeks of treatment and entire treatment were analyzed by stratified multivariable Cox models in relationship to OS/PFS. 55.7% pts received Oxa- regimens, 35.7% Iri-regimens, and 8.6% combined Oxa- and Iri-regimens. Results: Within the first 6 weeks of treatment, G3+ neutropenia (HR adj = 1.3, 95% CI, 1.06-1.59, p adj 0.01), diarrhea (HR adj = 1.48, 95% CI, 1.23-1.79, p adj &lt; .0001), nausea (HR adj = 1.53, 95% CI, 1.17-1.99, p adj 0.002) and vomiting (HR adj = 1.56, 95% CI, 1.18-2.07, p adj 0.002) were associated with significantly worse OS for Iri-regimens, but only G3+ nausea predicted for worse OS for Oxa- regimens (HR adj = 1.61, 95% CI, 1.18-2.21, p adj 0.003). For AEs experienced at any time, G3+ neutropenia and neuropathy were significantly associated with longer PFS and OS for Oxa-regimens, while G3+ vomiting and nausea were associated with worse OS for both Oxa- and Iri-based regimens. Sensitivity analysis showed largely concordant results by including pts who also received biologics. Conclusions: The association between more severe selected AEs and outcome varies between AEs and is influenced by timing of the occurrence. More severe selected AEs occurring early in treatment are associated with worse outcomes. In contrast, for AEs occurring at any time, G3+ neutropenia and neuropathy predicted for longer PFS and/or OS in Oxa-treated pts.
Does the bile acid receptor TGR5 play a role in Kupffer cell response during Alcoholic Liver Disease?
Authors: M. Spatz, D. Ciocan, F. Neuza, D. Rainteau, L. Humbert, C. Hugot, L. Wrzosek, P. Virginie, G. Ferrere, G. Perlemuter, T. Tordjmann, A.-M.C. Doulcier
Journal: Journal of Hepatology (2018)